Clinical article · Specialties, Surgery and trauma, Medicines and results

Anticoagulants and antiplatelets around surgery: stopping, bridging and restarting

Written for
Hospital physicians, anaesthetists, surgical teams and residents
Reading time
7 minutes
Published
Updated

Written by the Sana Health team for clinicians. It summarises published guidance, is not a guideline and has not been peer reviewed. Check current local protocols before acting.

Key points

  • Start with four facts: the bleeding risk of the procedure, the thrombotic risk of the patient, the drug with the kidney function, and whether a neuraxial or deep block is planned.
  • Direct oral anticoagulants are interrupted for standardised, drug- and kidney-specific periods, without heparin bridging.
  • Heparin bridging is for a few patients at very high thrombotic risk, chiefly those with a mechanical heart valve; it is not routine in atrial fibrillation.
  • Aspirin for secondary prevention is usually continued, and early interruption of dual antiplatelet therapy after a coronary stent is the main driver of peri-operative stent thrombosis.
  • Neuraxial anaesthesia needs its own interval, taken from a named regional anaesthesia guideline.
  • Restart only when haemostasis is secure, later after high-bleeding-risk surgery, and write the restart plan down.

Four facts before any decision

Most peri-operative harm from antithrombotic drugs comes from two opposite errors: stopping a drug that should have continued, and restarting one too early. The American College of Chest Physicians (ACCP) 2022 guideline covers vitamin K antagonists, heparin bridging, direct oral anticoagulants (DOACs) and antiplatelet drugs in patients having elective procedures [1], and recent reviews in JAMA summarise a standardised approach [2, 11]. Every plan starts from the same facts:

  • The bleeding risk of the procedure: minimal (for example minor dental or skin procedures), low to moderate (for example cholecystectomy or inguinal hernia repair) or high [2].
  • The thrombotic risk of the patient: the indication, recent events, valve type and, in atrial fibrillation, the CHA2DS2-VASc score.
  • The drug, dose and time of the last dose, with creatinine clearance estimated by Cockcroft-Gault.
  • Whether spinal, epidural or deep nerve block anaesthesia is planned.
  • The urgency: in an emergency the question changes from interruption to reversal.

Direct oral anticoagulants

Because DOACs have short, predictable half-lives, they can be stopped for a fixed period set by the drug, the kidney function and the bleeding risk of the procedure, and heparin bridging is not needed [1, 2]. Dabigatran depends most on renal clearance and needs a longer interruption when kidney function is reduced. Procedures with minimal bleeding risk can often be done with the DOAC continued or a single dose omitted, as agreed with the proceduralist [2].

SituationGeneral approachSource to follow
Minimal bleeding riskContinue, or omit a dose around the procedureThe proceduralist and local protocol [2]
Low to moderate bleeding riskShort standardised interruption, longer for dabigatran with reduced kidney function; no bridgingThe ACCP guideline [1] and the PAUSE protocol [3]
High bleeding riskLonger standardised interruption; no bridging; later restartThe ACCP guideline [1] and the PAUSE protocol [3]
Neuraxial anaesthesia or deep nerve blockThe interval set by the regional anaesthesia guideline, often longer, sometimes with a drug levelThe ASRA guideline or its national equivalent [3]

The two main approaches to neuraxial anaesthesia differ. The American Society of Regional Anesthesia (ASRA) guideline is conservative, with prolonged interruption and DOAC level testing in some circumstances, whereas the PAUSE protocol uses a simplified, standardised schedule [3]. The anaesthetist decides which applies, and the plan should give one interval for the patient's actual drug and dose rather than a range.

Warfarin and the bridging question

Warfarin is stopped several days before most procedures, with the INR checked beforehand and the timing set by the ACCP guideline and local protocol [1]. Some procedures are safer on continued anticoagulation: for pacemaker and defibrillator surgery, continuing warfarin rather than bridging with heparin reduced device pocket haematoma by 80% in the BRUISE CONTROL trial, and BRUISE CONTROL-2 went on to compare continued with interrupted DOACs [6].

Bridging with low-molecular-weight heparin was once routine. In the BRIDGE trial, patients with atrial fibrillation whose warfarin was interrupted were randomised to bridging or placebo; forgoing bridging was non-inferior for arterial thromboembolism and caused less major bleeding [4]. PERIOP2 randomised 1,471 patients with atrial fibrillation or mechanical heart valves to post-operative dalteparin or placebo [5]. The ACCP guideline suggests bridging for patients with a mechanical heart valve, and suggests against it in atrial fibrillation and when venous thromboembolism is the only indication; patients at the very highest thrombotic risk, such as those with a stroke or venous thromboembolism in the past three months, need an individual plan [1].

Antiplatelet drugs and coronary stents

Aspirin is a different decision in primary and secondary prevention. In POISE-2, perioperative aspirin did not reduce cardiovascular events after noncardiac surgery but increased major bleeding [8, 9], so there is little reason to start it for an operation. Patients with recent coronary stents were excluded from that trial, and for patients taking aspirin after a stent, myocardial infarction or stroke, guidelines favour continuing it through most surgery [7]. The exceptions are operations where bleeding into a closed space would be catastrophic, such as intracranial and spinal canal surgery and some eye procedures, which are discussed with the surgeon.

Interruption of dual antiplatelet therapy is the dominant risk factor for stent thrombosis and major cardiac events around surgery [10]. Elective surgery should be deferred until the minimum course of dual therapy recommended for the stent and indication is complete, following the ACC/AHA or ESC guideline [7]. When surgery cannot wait, aspirin is usually continued and the P2Y12 inhibitor stopped for a drug-specific interval (longest for prasugrel), then restarted as soon as bleeding risk allows. The plan is agreed with the cardiologist and surgeon, ideally in a hospital with interventional cardiology.

Restarting after surgery

  1. Confirm haemostasis with the surgeon before any anticoagulant is restarted.
  2. Resume DOACs sooner after low-to-moderate-risk procedures and later after high-bleeding-risk procedures, as the ACCP guideline sets out [1]; prophylactic-dose heparin can cover the gap when venous thromboembolism risk warrants.
  3. Restart warfarin once the patient is eating and bleeding risk allows, with INR monitoring, and bridge after surgery only in the highest-risk groups.
  4. Time removal of epidural and nerve catheters, and the first anticoagulant dose after removal, by the regional anaesthesia guideline.
  5. Resume the P2Y12 inhibitor as early as is safe in patients with recent stents.
  6. Write the restart plan, with dates, in the operation note and the discharge summary.

When surgery cannot wait

For emergency surgery the question becomes reversal. Record the time of the last dose and the kidney function, send a coagulation screen and, where available, a drug-specific level, and follow the local reversal protocol with haematology advice: vitamin K with prothrombin complex concentrate for warfarin, idarucizumab for dabigatran, and the agent used locally for factor Xa inhibitors. Antiplatelet effects are harder to reverse, and platelet transfusion is generally reserved for active bleeding.

Traps

  • Stopping aspirin in a patient with a coronary stent because the operation is described as major.
  • Bridging patients with atrial fibrillation out of habit.
  • Using the same DOAC interval for every patient, whatever the kidney function or the anaesthetic.
  • Quoting a range of intervals for neuraxial anaesthesia that includes an unsafe value.
  • Restarting full-dose anticoagulation on the evening of high-bleeding-risk surgery.
  • Losing the restart plan between theatre, ward and discharge.

Intervals differ between national and society guidelines, licensed product information differs between countries, and local anaesthetic, haematology and surgical protocols take precedence over this summary.

How Sana Health helps

The Peri-operative Assessment engine returns a medication plan as a table: each medicine, what to do before surgery, on the day and afterwards. For anticoagulants it works from the drug, dose, creatinine clearance and the bleeding risk of the procedure; for antiplatelets, from the indication and the stent type and date; and when neuraxial anaesthesia is planned, it gives the interval from a named regional anaesthesia guideline. It states whether bridging is indicated, lists numbered PubMed references, and attaches US product labels from DailyMed when named medicines are involved.

Questions

Do patients on a DOAC need heparin bridging before surgery?

No. DOACs wear off and take effect quickly, so a planned interruption does not need heparin cover, and the ACCP guideline advises against bridging. Prophylactic-dose heparin may be used after surgery until the DOAC is restarted.

Should warfarin be continued for pacemaker implantation?

Often, yes. Continuing warfarin rather than bridging with heparin reduced device pocket haematoma in the BRUISE CONTROL trial. The implanting team sets the INR target and decides whether a DOAC should be continued or briefly interrupted.

How long after a coronary stent can elective surgery be done?

Elective surgery is deferred until the minimum course of dual antiplatelet therapy recommended for the stent and the indication is complete. The duration differs between ACC/AHA and ESC guidance and depends on whether the stent was placed for an acute coronary syndrome, so the timing is agreed with the cardiologist.

References

  1. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline (opens in a new tab)Chest, 2022
  2. Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review (opens in a new tab)JAMA, 2024
  3. Direct oral anticoagulant management for neuraxial anaesthesia and deep peripheral nerve blocks (opens in a new tab)Br J Anaesth, 2025
  4. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation (opens in a new tab)N Engl J Med, 2015
  5. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial (opens in a new tab)BMJ, 2021
  6. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2) (opens in a new tab)Eur Heart J, 2018
  7. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines (opens in a new tab)Circulation, 2024
  8. Effect of aspirin in vascular surgery in patients from a randomized clinical trial (POISE-2) (opens in a new tab)Br J Surg, 2018
  9. Perioperative aspirin management after POISE-2: some answers, but questions remain (opens in a new tab)Anesth Analg, 2015
  10. Coronary stents: factors contributing to perioperative major adverse cardiovascular events (opens in a new tab)Br J Anaesth, 2010
  11. Perioperative Management of Antithrombotic Therapy (opens in a new tab)JAMA, 2024